The Biomarker Discovery & Translational Research Laboratory at the National Hellenic Research Foundation (NHRF) operates at the interface of discovery science and innovation, transforming datasets into actionable insights.
At the core of its strategy lies proteoform-based drug repurposing (a next-generation approach that leverages the functional diversity of proteins, including post-translational modifications and isoforms) to identify precise, mechanism-driven therapeutic opportunities. This enables a more refined and translatable path to repurposing drugs, advanced materials and smart systems with greater confidence and clinical relevance. To support this, the lab has launched IN3© (In Silico–In Vitro–In Vivo), a proprietary innovation engine that unifies computational modelling, advanced experimental systems and translational validation into a seamless pipeline. IN3 enables rapid prioritisation, de-risking and validation, generating intellectual property.

Core capabilities include:

• Proteoform-resolved multi-omics and extracellular vesicle profiling.
• AI-powered data integration, machine learning and structure-informed modelling.
• Advanced 3D cellular systems (NAMs) and physiologically relevant ADME-Tox platforms.
• Cross-scale validation from molecular mechanisms to system-level responses.

Extending this vision into scalable innovation, the lab has co-developed Cloudscreen®, an AI-driven platform for drug repurposing and screening, in partnership with CLOUDPHARM PC, where leadership also plays an active executive role. Positioned as a “one-stop-shop” for translational innovation, the lab serves both as a partner and a CRO, delivering integrated solutions that accelerate the journey from data to decision and from discovery to impact.